Compared with MDS/MPN-RS-T, one of the key modifications of the 2022 WHO classification for MDS/MPN-SF3B1-T was that patient with <15% bone marrow RS and SF3B1 mutations were newly involved in the disease. This evidence concerns the gene SF3B1 and myeloproliferative neoplasm.